These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 23099497

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H, Taei R, Riazi-Esfahani M, Piri N, Homayouni M, Daftarian N, Yaseri M.
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Jun; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 10. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

  • 17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X, Li J, Hu X, Yu S, Pan J, Tang S.
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF.
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [Abstract] [Full Text] [Related]

  • 19. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB, Lund-Andersen H, Sander B, Larsen M.
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD.
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.